We measured the onset, level and reversibility of tau phosphorylation using immunoblotting and immunostaining with AT8, AT100 and Ser396, antibodies that detect phosphorylation at well-documented abnormal tau phosphorylation sites (AT8: Ser202 and Thr205, AT100: Thr212 and Ser214) and are commonly used for post-mortem biochemical staging of AD [13]. This evidence concerns the gene MAPT and Alzheimer disease.